Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 17/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | MC5R | P33032 | 1/20 | 0.40 |
| ▸ | MC3R | P41968 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25421666 | 0.95 | MC4R (1.00) | MC4RKCNH2MC5RMC3REGFR | |
| SCHEMBL30996495 | 0.95 | MC4R (1.00) | MC4RKCNH2MC5RMC3REGFR | |
| SCHEMBL31666916 | 0.90 | MC4R (0.91) | MC4RKCNH2MC5RMC3REGFR | |
| SCHEMBL25437050 | 0.90 | MC4R (0.85) | MC4RKCNH2MC5RMC3REGFR | |
| SCHEMBL30458072 | 0.90 | MC4R (0.85) | MC4RKCNH2MC5RMC3REGFR | |
| SCHEMBL30996497 | 0.88 | MC4R (0.86) | MC4RKCNH2MAPK1 | |
| SCHEMBL25275069 | 0.86 | MC4R (0.92) | MC4RKCNH2MC5RMC3REGFR | |
| SCHEMBL25227906 | 0.86 | MC4R (0.92) | MC4RKCNH2MC5RMC3REGFR | |
| SCHEMBL25439203 | 0.86 | MC4R (1.00) | MC4RKCNH2MC5RMC3REGFR | |
| SCHEMBL31421661 | 0.86 | MC4R (1.00) | MC4RKCNH2MC5RMC3REGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444708-B1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER (US) | 2025-07-30 | — | — | EP | claimed |
| US-20250129048-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-04-24 | — | — | US | claimed |
| CN-118369317-A | Melanocortin 4 receptor antagonists and uses thereof | 辉瑞大药厂 | 2024-07-19 | — | — | CN | claimed |
| EP-4444708-B1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250129048-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4444708-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-118369317-A | Melanocortin 4 receptor antagonists and uses thereof | 辉瑞大药厂 | 2024-07-19 | — | — | CN | disclosed |
| WO-2023105387-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129048-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | MC4R, MC3R, MC2R | MC4R 1/4885KCNH2 3260/4885MC5R 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.